2-(3-Oxocyclopentyl)isoindoline-1,3-dione, 95.0%, 1g

8-Chloro-6-methylquinolin-2(1H)-one, 98%, 1g

Methyl 2-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-3-carboxylate, 98%, 500mg

6-(4-Chlorophenyl)morpholin-3-one, 98%, 500mg

Ethyl 2-Phenyl-1,3-oxazole-4-carboxylate, 97.0%, 250mg

2-ACETYL-NICOTINIC ACID ETHYL ESTER, 90.0%, 50mg

3-(Trifluoromethyl)phenyl isothiocyanate, 98.0%, 5g

(4,4-Difluorocyclohexyl)hydrazine dihydrochloride, 98%, 500mg

9-(2-Bromoethyl)-9H-purin-6-amine, 95.0%, 1g

3-AMINO-3-(PYRIDIN-2-YL)PROPANOIC ACID DIHYDROCHLORIDE, 95%, 1g

(4-(1H-Pyrazol-1-yl)phenyl)boronic acid, 95.0%, 1g

(2E)-1-(3,4-dichlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one, 95.0%, 2g

E-Plan fase EPLPH objetivo 10x/0,25. Distancia de trabajo 6,61 mm